News Enhertu scores again in early breast cancer AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.
News Enanta weakens on RSV treatment trial readout Shares in Enanta Pharma were sliding this morning after it reported results of a phase 2b trial of its RSV antiviral zelicapavir.
News AstraZeneca hops on the DTC sales train in the US AstraZeneca has become the latest pharma group to set up a direct-to-consumer sales channel in the US, covering Farxiga, Airsupra, and FluMist.
News Genmab agrees $8bn takeover of cancer biotech Merus Genmab continues its shift from out-licensing drugs to developing its own drugs with an $8bn deal to buy Merus and its head and neck cancer therapy.
News Walmsley to leave GSK in surprise exit This week has kicked off with the news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by Luke Miels.
News FDA will review abortion pill safety – will it be impartial? The Trump administration's linking of autism to Tylenol and vaccines with no evidence raises concern about an FDA review of mifepristone's safety.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
